FDA will ask its Arthritis Advisory Committee at a July 22-23 meeting whether axial spondyloarthritis is a sufficiently well understood and defined population to support new indications for two TNF inhibitors.
The panel will be asked to consider whether recently developed criteria for classifying patients with axial spondyloarthritis (axial SpA), a broad spectrum of chronic inflammatory disease that primarily affects the axial skeleton, can be used to define a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?